Saxenda vs Ozempic: Which Is Right for You?

If you’ve been researching GLP-1 medications for weight loss, you’ve probably come across both Saxenda and Ozempic. They belong to the same drug class, they work through similar mechanisms, and they’re both prescribed for weight management. But there are meaningful differences between them that matter when you’re deciding which direction to go. This breakdown covers how they compare on efficacy, dosing, side effects, and cost so you can have a more informed conversation with your provider.

The Basic Difference: Same Class, Different Molecules

Both Saxenda and Ozempic are GLP-1 receptor agonists, meaning they mimic the glucagon-like peptide-1 hormone that regulates appetite, slows gastric emptying, and influences insulin secretion. That shared mechanism is why they produce similar effects: reduced appetite, smaller portion sizes, and gradual weight loss.

The difference is in the specific molecule each medication uses.

Saxenda’s active ingredient is liraglutide, a GLP-1 agonist that has a shorter duration of action in the body, which is why it requires daily injections. Ozempic’s active ingredient is semaglutide, a structurally modified GLP-1 agonist with a much longer half-life, allowing for once-weekly dosing.

This distinction in dosing frequency is one of the most practically significant differences between the two medications for most people.

Dosing and Administration

Saxenda is injected daily, typically at the same time each day. The starting dose is 0.6mg, escalating over five weeks to the full maintenance dose of 3mg per day. That’s 365 injections per year.

Ozempic is injected once weekly. The starting dose for weight loss is 0.25mg, escalating over several weeks to 0.5mg, 1mg, or 2mg depending on response and tolerability. That’s 52 injections per year.

For most people, the convenience gap here is significant. Daily injections require a consistent daily habit, more supplies, and more opportunities to miss a dose. Weekly injections are easier to build into a routine and harder to forget.

How the Weight Loss Results Compare

Clinical trial data shows a clear efficacy advantage for semaglutide over liraglutide. In the SCALE trial, Saxenda produced an average weight loss of around 8% of body weight over 56 weeks. In the STEP trials, semaglutide at 2.4mg (the dose used in Wegovy, the weight-loss-approved version) produced average weight loss of nearly 15% of body weight over 68 weeks.

That’s a meaningful difference. Semaglutide consistently outperforms liraglutide in head-to-head comparisons, producing roughly double the weight loss in clinical settings.

For people who tried Saxenda and found results underwhelming, switching to a semaglutide-based medication is a clinically reasonable next step. The stronger appetite suppression and longer duration of action appear to drive meaningfully better outcomes for most patients.

Side Effect Profiles

Both medications share a similar side effect profile because of their shared mechanism. The most common side effects for both include nausea, vomiting, diarrhea, constipation, and decreased appetite. These tend to be most pronounced during dose escalation and improve for most people once they reach a stable dose.

Some differences worth noting:

Because Saxenda requires daily dosing, side effects are a daily variable. If nausea is an issue, it’s a daily issue rather than a once-weekly one. Some people find this harder to manage than the concentrated side effect window that can come with a weekly injection.

Both medications carry similar contraindications, including a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Both also carry a similar rare risk of pancreatitis.

Cost Comparison

This is where the conversation gets more practical for many people. Saxenda’s list price runs around $1,300 to $1,400 per month without insurance. Ozempic’s list price is in a similar range, though insurance coverage varies by indication.

The more significant cost consideration is that semaglutide is available as a compounded medication through telehealth providers at a fraction of the brand-name cost. Compounded liraglutide is not widely available in the same way, which means the cost advantage for semaglutide-based treatment is substantial for people paying out of pocket.

For people exploring how to get GLP-1 medications without insurance, compounded semaglutide is typically the most accessible and affordable entry point into GLP-1 treatment.

Who Might Still Choose Saxenda

Given the efficacy and convenience advantages of semaglutide, it’s worth asking whether there’s a scenario where Saxenda makes more sense.

A few situations where liraglutide might be preferred:

Some patients have tried semaglutide and experienced side effects that were difficult to tolerate, and find liraglutide’s daily lower doses more manageable. Individual responses to these medications vary.

Saxenda has a longer track record specifically as a weight loss medication. It received FDA approval for chronic weight management in 2014, while the weight-loss-specific semaglutide approval (Wegovy) came in 2021. For providers or patients who want the longest available safety history in a weight-loss-approved GLP-1, liraglutide has that edge by a few years.

In some insurance scenarios, coverage for Saxenda may be more established than for newer semaglutide approvals, though this varies widely by plan and is worth checking individually.

Making the Decision

For most people starting GLP-1 treatment for weight loss today, semaglutide-based medications offer stronger results, more convenient dosing, and better cost accessibility through compounded options. Saxenda was a meaningful step forward when it launched, but the data consistently shows semaglutide outperforming it.

Consider this scenario: a patient who tried Saxenda for six months, lost about 12 pounds, but struggled with daily injections and found the results plateaued earlier than expected. Switching to compounded semaglutide, they find the weekly dosing easier to maintain and lose an additional 20 pounds over the following year. That pattern is common enough that providers often recommend semaglutide as a first-line option now rather than starting with liraglutide.

If you’re currently on Saxenda and wondering whether switching makes sense, it’s a conversation worth having with your provider. If you’re comparing options before starting treatment, the TrimRx intake quiz can help you identify which medication fits your health profile and goals.

For a broader look at how semaglutide compares to tirzepatide, which represents the next generation of GLP-1 treatment, the semaglutide to tirzepatide switching guide covers what that transition looks like and who it tends to benefit most.

A study published in Diabetes, Obesity and Metabolism confirmed that semaglutide produced significantly greater reductions in body weight compared to liraglutide in a direct head-to-head trial, reinforcing the clinical consensus that semaglutide represents a meaningful advancement over first-generation GLP-1 agonists for weight management.

This information is for educational purposes and is not medical advice. Consult with a healthcare provider before starting any medication. Individual results may vary.